EACR Defence is the Best Attack: Immuno-Oncology Breakthroughs

This popular EACR conference returns for its 6th edition in May 2027 – will you join us in Barcelona for a broad but detailed exploration of the latest findings in immuno-oncology?

Our panel of experts will provide a deeper understanding of the molecular mechanisms involved in interactions between tumours and the immune system, highlighting how they can reveal new approaches to cancer therapies. From the basic science to recent clinical studies, they’ll cover the mechanisms of action of various treatments and discuss both biomarkers of treatment response and immunotherapy resistance, whether intrinsic or acquired.

Whether you’re a basic or translational scientist, a clinician, or a scientific journalist, if you’re interested in learning more about cancer immunotherapies then this is the conference for you.

Submit an abstract by 08 March 2027 for the chance to present your work and register by 12 April 2027 to join the conversation in Barcelona. Travel Grants are available for those who need financial assistance to attend.

Speakers: Leila Akkari (NKI, Amsterdam) | Direna Alonso-Curbelo (IRB Barcelona, Spain) | Christoph Bock (CeMM Research Centre for Molecular Medicine & Medical University of Vienna, Austria) | Alena Gros (VHIO, Spain) | Carl June (University of Pennsylvania, USA) | Marleen Kok (NKI, Amsterdam) | Marcela Maus (Harvard Medical School, USA) | Miriam Merad (Icahn School of Medicine at Mount Sinai, USA) | Anna Obenauf (IMP, Austria) | Christoph Scheiermann (LMU Munich, Germany & University of Geneva, Switzerland) | Ton Schumacher (NKI, Netherlands) | Joan Seoane (VHIO, Spain) | Lillian Siu (Princess Margaret Cancer Centre & University of Toronto, Canada) | Marion Subklewe (LMU Klinikum, Germany) | Charles Swanton (Francis Crick Institute, UK)

Keywords: cancer research, oncology, cancer immunology, immuno-oncology, novel target identification, biomarkers of therapy response, intrinsic resistance, acquired resistance, cancer vaccines, immune checkpoints, CAR-T cells, T-cell engagers, immune-evasive tumour microenvironment, cancer plasticity, cancer metabolism, tumour antigens, cancer genomics, cancer epigenetics, AI, cell engineering, cancer prevention